These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26308504)

  • 1. Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes.
    Lean QY; Gueven N; Eri RD; Bhatia R; Sohal SS; Stewart N; Peterson GM; Patel RP
    Expert Rev Clin Pharmacol; 2015; 8(6):795-811. PubMed ID: 26308504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials.
    Chande N; MacDonald JK; Wang JJ; McDonald JW
    Inflamm Bowel Dis; 2011 Sep; 17(9):1979-86. PubMed ID: 21618363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis.
    Panés J; Esteve M; Cabré E; Hinojosa J; Andreu M; Sans M; Fernandez-Bañares F; Feu F; Gassull MA; Piqué JM
    Gastroenterology; 2000 Oct; 119(4):903-8. PubMed ID: 11040177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond.
    Malhotra S; Bhasin D; Shafiq N; Pandhi P
    Expert Opin Pharmacother; 2004 Feb; 5(2):329-34. PubMed ID: 14996629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C; Wiebecke B; Loeschke K
    Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for the treatment of ulcerative colitis.
    Eshuis EJ; Bemelman WA; Stokkers PC
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):219-29. PubMed ID: 19485804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin therapy for ulcerative colitis? Effects and mechanisms.
    Michell NP; Lalor P; Langman MJ
    Eur J Gastroenterol Hepatol; 2001 Apr; 13(4):449-56. PubMed ID: 11338079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis.
    Pastorelli L; Saibeni S; Spina L; Signorelli C; Celasco G; de Franchis R; Vecchi M
    Aliment Pharmacol Ther; 2008 Sep; 28(5):581-8. PubMed ID: 18700898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease.
    Papa A; Danese S; Gasbarrini A; Gasbarrini G
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1403-9. PubMed ID: 11069310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.
    Bressler B; Marshall JK; Bernstein CN; Bitton A; Jones J; Leontiadis GI; Panaccione R; Steinhart AH; Tse F; Feagan B;
    Gastroenterology; 2015 May; 148(5):1035-1058.e3. PubMed ID: 25747596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin in the treatment of inflammatory bowel disease: dare we take the risk?
    Bensen S
    Inflamm Bowel Dis; 2001 Aug; 7(3):277-9. PubMed ID: 11515857
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease.
    Ang YS; Mahmud N; White B; Byrne M; Kelly A; Lawler M; McDonald GS; Smith OP; Keeling PW
    Aliment Pharmacol Ther; 2000 Aug; 14(8):1015-22. PubMed ID: 10930895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of coagulation and hemostasis in inflammatory bowel diseases.
    Stadnicki A
    Curr Vasc Pharmacol; 2012 Sep; 10(5):659-69. PubMed ID: 22272910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: The utility and safety of heparin in the treatment of active ulcerative colitis.
    Shen J; Ran ZH; Tong JL; Xiao SD
    Aliment Pharmacol Ther; 2007 Sep; 26(5):653-63. PubMed ID: 17697199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From unfractionated heparins to low molecular weight heparins.
    Hirsh J
    Acta Chir Scand Suppl; 1990; 556():42-50. PubMed ID: 1705072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
    Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
    Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current pharmacologic therapies and emerging alternatives in the treatment of ulcerative colitis.
    Nakamura T; Nagahori M; Kanai T; Watanabe M
    Digestion; 2008; 77 Suppl 1():36-41. PubMed ID: 18204260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulcerative colitis: prevention of relapse.
    Naganuma M; Sakuraba A; Hibi T
    Expert Rev Gastroenterol Hepatol; 2013 May; 7(4):341-51. PubMed ID: 23639092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.